In our diverse world, embracing our differences is key. Every unique perspective and experience help enhance our collective understanding and fuels innovation. And, when we embrace diversity, we help foster a culture of inclusion and empathy. Listen as Organon’s Tejal Shah discusses how she shares her unique heritage, as well as seeks to learn about others, through her involvement in Organon’s Employee Resource Groups. #GlobalDiversityAwarenessMonth
Organon
Pharmaceutical Manufacturing
Jersey City, NJ 135,149 followers
Here for her health
About us
Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself against recruiting fraud from individuals, organizations or other entities claiming to represent Organon. All official Organon recruitment emails will come from accounts formatted as [email protected] or [email protected], and Organon will never conduct interviews by chat or email, or make job offers through social media or online forums. All candidates for roles at Organon will first meet with a recruiter and interview team, via Teams or in person. Organon will never ask you to make financial transactions on its behalf or ask you to receive or ship packages or goods. For more information on adverse event reporting, visit http://bit.ly/AEReporting. To read our community guidelines, visit http://bit.ly/OrganonCommunityGuidelines. Follow us on Twitter at Organon (@OrganonLLC). Follow us on Instagram at Organon (@OrganonLLC).
- Website
-
http://www.organon.com
External link for Organon
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Jersey City, NJ
- Type
- Public Company
- Specialties
- Pharmaceutical
Locations
-
Primary
30 Hudson Street
Jersey City, NJ 07302, US
Employees at Organon
Updates
-
In the latest issue of Fortune Italia, Organon CEO Kevin Ali discusses our efforts in R&D and focusing on potential solutions for the health of a woman, as well as enabling demographic resilience. This means adapting to demographic changes related to unintended pregnancies, falling birth rates and aging populations to maintain social, economic, and environmental stability. Watch to hear Kevin speak about how the power of public-private partnerships is crucial to creating a sustainable future. #DemographicResilience #FamilyPlanning #PublicPrivatePartnerships
-
In 2024, it is estimated that there will be 310,720 new cases of female breast cancer, according to the National Cancer Institute. According to the American Cancer Society, most of these women will receive treatment and survive for many years. Supporting a breast cancer patient throughout their journey includes a team of healthcare professionals working together to ensure a patient’s needs are met – from physical to emotional – no matter where they are in their journey. Today, we are recognizing the survivors, forever fighters, and their care teams that make all the difference. To all the doctors, nurses, nurse practitioners, administrators, physician assistants, pharmacists, staff, case managers, nurse navigators, and others, thank you for everything you do each and every day. #BreastCancerAwarenessMonth #BreastCancerAwareness
-
#Migraines – a potentially debilitating condition that affects ~1 billion people globally – are more than just headaches; they may cause severe pain, nausea, and sensitivity to light and sound, potentially impacting daily life. Although men and women can experience migraines, women are three times as likely as men to experience them. If you or someone you know suffers from migraines, remember you're not alone. At Organon, we’re committed to supporting those with migraine by improving access to treatment options and helping reduce the stigma associated with this condition. #PainAwarenessMonth #MigraineAwareness #Migraine #ChronicPain
-
Today, we announced with Shanghai Henlius Biotech that the phase 3 comparative clinical trial for an investigational #biosimilar met its primary endpoint. Read the #news here: https://ogn.llc/6047mYtSb
Learn About Further Development in the Biosimilar Space
-
High cholesterol often shows no symptoms. It can quietly build up and increase your risk of cardiovascular disease (CVD)—the leading cause of death—that often goes underdiagnosed and undertreated in women. Don’t miss these red flags when it comes to your health, so you can manage cholesterol levels and help reduce your risk of CVD. #WorldHeartDay #CholesterolEducationMonth
-
In the U.S., despite a large increase in the number of #biosimilars available, uptake has been slower than expected. Savings from biosimilars have more than tripled from 2019 to 2020 to nearly $8 billion. Organon is committed to making a difference by supporting the adoption of biosimilars across the health care system, so patients have better access to potentially more affordable treatments. Learn more at: https://ogn.llc/6045mgMoc
-
In the U.S., the American College of Obstetricians and Gynecologists (ACOG) defines postpartum hemorrhage (PPH) as blood loss of ≥1,000 mL post-delivery (either vaginal or cesarean). From 2016-2022, PPH and abnormal postpartum uterine bleeding rates rose from 12% to 20%, according to one study presented at #SMFM24, authored by: Dr. Patricia Carney, MD, FACOG, Candice Young, Brian Seal, and Seungyoung Hwang (Organon), Dr. Kara Rood (The Ohio State University-Wexner Medical Center), Dr. Roy Brooks (Capital Women’s Care & Holy Cross Hospital). The study also explored some of the changing treatment patterns over this time. When it comes to PPH, early intervention is crucial. According to ACOG, “earlier recognition of postpartum hemorrhage (eg, before deterioration in vital signs) should be the goal in order to improve outcomes.” At Organon, we also understand the critical importance of supporting those affected by this condition and are committed to working with like-minded partners and innovators to enhance education and access to treatment options that aim to address PPH. #MaternalHealth #PostpartumHemorrhage #PPH #MedicalResearch
-
Misinformation about birth control and reproductive care is a growing health concern. Confusion, information overload, myths, and anecdotal experiences flood our screens, feeds and conversations on a daily basis which can influence the decision-making process. Inaccurate information can potentially contribute to higher unintended pregnancy rates and misunderstandings about birth control – this can be detrimental to women and their community. Part of Organon’s aim is to help ensure quality care and fact-based access to information for women and girls. By educating about reproductive health, we strive to inspire, empower, and uplift. Learn more from Dr. Charlotte Owens, MD, FACOG, Head of Medical Affairs & Outcomes Research at Organon, in The New York Times: https://ogn.llc/6009m5V9t #WCD2024 #ThxBirthControl #ReproductiveHealth #Contraception #WomensHealth
-
Sexual health matters at any age. Important screenings like the Pap Smear and preventive measures are important for every woman to consider. We’re committed to advancing the complete health of women at all stages of their life journey to help ensure they can get the care they deserve. #SexualHealthAwarenessMonth #HealthyAgingMonth